Literature DB >> 18854487

Human genetic factors and respiratory syncytial virus disease severity.

Isao Miyairi1, John P DeVincenzo.   

Abstract

SUMMARY: To explain the wide spectrum of disease severity caused by respiratory syncytial virus (RSV) and because of the limitations of animal models to fully parallel human RSV disease, study of genetic influences on human RSV disease severity has begun. Candidate gene approaches have demonstrated associations of severe RSV in healthy infants with genetic polymorphisms that may alter the innate ability of humans to control RSV (surfactants, Toll-like receptor 4, cell surface adhesion molecules, and others) and those that may control differences in proinflammatory responses or enhanced immunopathology (specific cytokines and their receptors). These studies are reviewed. They are valuable since an understanding of the direction of a polymorphism's effect can help construct a meaningful human RSV disease pathogenesis model. However, the direction, degree, and significance of the statistical association for any given gene are equivocal among studies, and the functional significance of specific polymorphisms is often not even known. Polymorphism frequency distribution differences associated with RSV infection arising from diversity in the genetic background of the population may be confounded further by multiple-hypothesis testing and publication bias, as well as the investigator's perceived importance of a particular pathogenic disease process. Such problems highlight the limitation of the candidate gene approach and the need for an unbiased large-scale genome-wide association study to evaluate this important disease.

Entities:  

Mesh:

Year:  2008        PMID: 18854487      PMCID: PMC2570150          DOI: 10.1128/CMR.00017-08

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  136 in total

1.  Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine.

Authors:  H W Kim; J G Canchola; C D Brandt; G Pyles; R M Chanock; K Jensen; R H Parrott
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

2.  Evidence for linkage between asthma/atopy in childhood and chromosome 5q31-q33 in a Japanese population.

Authors:  E Noguchi; M Shibasaki; T Arinami; K Takeda; T Maki; T Miyamoto; T Kawashima; K Kobayashi; H Hamaguchi
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

3.  Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease.

Authors:  S Aung; J A Rutigliano; B S Graham
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

4.  Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa.

Authors:  C J Edwards-Smith; J R Jonsson; D M Purdie; A Bansal; C Shorthouse; E E Powell
Journal:  Hepatology       Date:  1999-08       Impact factor: 17.425

5.  Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility.

Authors:  D Hacking; J C Knight; K Rockett; H Brown; J Frampton; D P Kwiatkowski; J Hull; I A Udalova
Journal:  Genes Immun       Date:  2004-06       Impact factor: 2.676

Review 6.  Respiratory syncytial virus and pulmonary surfactant.

Authors:  Matthias Griese
Journal:  Viral Immunol       Date:  2002       Impact factor: 2.257

7.  Interleukin (IL)-18 polymorphism 133C/G is associated with severe respiratory syncytial virus infection.

Authors:  Beena Puthothu; Marcus Krueger; Johannes Forster; Jessica Heinze; Markus Weckmann; Andrea Heinzmann
Journal:  Pediatr Infect Dis J       Date:  2007-12       Impact factor: 2.129

8.  Respiratory syncytial viral infection in children with compromised immune function.

Authors:  C B Hall; K R Powell; N E MacDonald; C L Gala; M E Menegus; S C Suffin; H J Cohen
Journal:  N Engl J Med       Date:  1986-07-10       Impact factor: 91.245

9.  TLR-4 and CD14 polymorphisms in respiratory syncytial virus associated disease.

Authors:  Beena Puthothu; Johannes Forster; Andrea Heinzmann; Marcus Krueger
Journal:  Dis Markers       Date:  2006       Impact factor: 3.434

10.  Toll-like receptor 4 is not involved in host defense against respiratory tract infection with Sendai virus.

Authors:  Koenraad F van der Sluijs; Leontine van Elden; Monique Nijhuis; Rob Schuurman; Sandrine Florquin; Henk M Jansen; René Lutter; Tom van der Poll
Journal:  Immunol Lett       Date:  2003-10-31       Impact factor: 3.685

View more
  44 in total

Review 1.  Immunogenomics and systems biology of vaccines.

Authors:  Luigi Buonaguro; Bali Pulendran
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  The pulmonary collectins and respiratory syncytial virus: is there a clinical link?

Authors:  Paul S Kingma; Jeffrey A Whitsett
Journal:  J Pediatr       Date:  2010-03       Impact factor: 4.406

Review 3.  Therapeutic targeting of respiratory syncytial virus G-protein.

Authors:  Lawrence M Kauvar; Jennifer L Harcourt; Lia M Haynes; Ralph A Tripp
Journal:  Immunotherapy       Date:  2010-09       Impact factor: 4.196

4.  Novel inflammatory markers, clinical risk factors and virus type associated with severe respiratory syncytial virus infection.

Authors:  Christy M Tabarani; Cynthia A Bonville; Manika Suryadevara; Patrick Branigan; Dongliang Wang; Danning Huang; Helene F Rosenberg; Joseph B Domachowske
Journal:  Pediatr Infect Dis J       Date:  2013-12       Impact factor: 2.129

Review 5.  Pathogenesis of acute respiratory illness caused by human parainfluenza viruses.

Authors:  Henrick Schomacker; Anne Schaap-Nutt; Peter L Collins; Alexander C Schmidt
Journal:  Curr Opin Virol       Date:  2012-03-03       Impact factor: 7.090

6.  Rhinovirus-associated wheeze during infancy and asthma development.

Authors:  Tuomas Jartti; James E Gern
Journal:  Curr Respir Med Rev       Date:  2011-06-01

7.  Construction of a large scale integrated map of macrophage pathogen recognition and effector systems.

Authors:  Sobia Raza; Neil McDerment; Paul A Lacaze; Kevin Robertson; Steven Watterson; Ying Chen; Michael Chisholm; George Eleftheriadis; Stephanie Monk; Maire O'Sullivan; Arran Turnbull; Douglas Roy; Athanasios Theocharidis; Peter Ghazal; Tom C Freeman
Journal:  BMC Syst Biol       Date:  2010-05-14

8.  Vaccines against respiratory syncytial virus: The time has finally come.

Authors:  Barney S Graham
Journal:  Vaccine       Date:  2016-05-13       Impact factor: 3.641

9.  TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.

Authors:  Teresa R Johnson; Srinivas Rao; Robert A Seder; Man Chen; Barney S Graham
Journal:  Vaccine       Date:  2009-04-03       Impact factor: 3.641

Review 10.  Respiratory viruses and eosinophils: exploring the connections.

Authors:  Helene F Rosenberg; Kimberly D Dyer; Joseph B Domachowske
Journal:  Antiviral Res       Date:  2009-04-16       Impact factor: 5.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.